Theravance Biopharma, Inc. (TBPH)
17.08
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
17.08
0.00 (0.00%)
After-Hours: 20:00
Theravance Biopharma Cash from Investing (Quarterly) : -60.40M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -60.40M |
| March 31, 2026 | 52.59M |
| December 31, 2025 | 0.588M |
| September 30, 2025 | -100.25M |
| June 30, 2025 | -36.26M |
| March 31, 2025 | 30.63M |
| December 31, 2024 | 15.69M |
| September 30, 2024 | -17.40M |
| June 30, 2024 | -3.031M |
| March 31, 2024 | 17.03M |
| December 31, 2023 | -0.677M |
| September 30, 2023 | -0.021M |
| June 30, 2023 | 11.05M |
| March 31, 2023 | -43.05M |
| December 31, 2022 | 39.16M |
| September 30, 2022 | 1.075B |
| June 30, 2022 | 7.515M |
| March 31, 2022 | 31.92M |
| December 31, 2021 | 10.82M |
| September 30, 2021 | -35.79M |
| June 30, 2021 | 35.77M |
| March 31, 2021 | 113.70M |
| December 31, 2020 | 52.40M |
| September 30, 2020 | 66.50M |
| June 30, 2020 | -176.59M |
| Date | Value |
|---|---|
| March 31, 2020 | 68.40M |
| December 31, 2019 | 14.06M |
| September 30, 2019 | -23.66M |
| June 30, 2019 | -1.296M |
| March 31, 2019 | -72.16M |
| December 31, 2018 | 99.39M |
| September 30, 2018 | 46.65M |
| June 30, 2018 | 41.96M |
| March 31, 2018 | -11.29M |
| December 31, 2017 | 41.25M |
| September 30, 2017 | 14.76M |
| June 30, 2017 | 11.18M |
| March 31, 2017 | -123.52M |
| December 31, 2016 | -46.20M |
| September 30, 2016 | -49.84M |
| June 30, 2016 | -68.58M |
| March 31, 2016 | 16.38M |
| December 31, 2015 | -34.50M |
| September 30, 2015 | 62.09M |
| June 30, 2015 | 41.30M |
| March 31, 2015 | 42.15M |
| December 31, 2014 | 9.684M |
| September 30, 2014 | -109.86M |
| June 30, 2014 | -4.459M |
| March 31, 2014 | -1.62M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Zymeworks, Inc. | 16.67M |
| Viatris, Inc. | -51.60M |
| Ocular Therapeutix, Inc. | -3.367M |
| ANI Pharmaceuticals, Inc. | -3.054M |
| Corcept Therapeutics, Inc. | -29.24M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.965M |
| Cash from Financing (Quarterly) | -0.967M |
| Free Cash Flow | 53.73M |
| Free Cash Flow Per Share (Quarterly) | -0.1348 |
| Free Cash Flow to Equity (Quarterly) | -5.03M |
| Free Cash Flow to Firm (Quarterly) | -6.965M |
| Free Cash Flow Yield | 6.05% |